CAR-T细胞技术是一种革命性的细胞疗法,2017年诺华公司推出第一代CAR-T疗法,这引领了其他形式的CAR-T药物的发展。 在23日的大会上,Dolcera中国区生物医药首席专家金实为大家带来“CAR-T Cell Therapy专利态势及研发趋势分析”相关观点分享。 知产前沿现将金老师的现场主题发言内容整理成文,供医药知识产权从业人员参考...
经CAR-T治愈的幸运小女孩Emily从12年接受治疗后,一直有安全性随访,她每年也会拍一张照片po到社交网站上。 相关链接及参考: Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL | Novartiswww.nova...
CAR-T(Chimeric Antigen Receptor T-cell therapy)细胞疗法是一种革命性的免疫治疗手段,通过基因工程技术改变患者自体T细胞,使其能够更有效地识别和攻击肿瘤细胞。该疗法在治疗血液肿瘤方面取得了显著成效,例如某些类型的淋巴瘤和白血病,已经被FDA批准上市。近年来,随着制药技术的进步,CAR-T细胞疗法的应用范围不断扩展至...
CAR T Cell Therapy Market Report published by value market research, it provides a comprehensive market analysis which includes market size, share, value, growth, trends during forecast period 2019-2025 along with strategic development of the key player with their market share. Further, the market...
The CAR T-cell therapy market is expected to clock a CAGR of30.6%during the assessment period. The CAR T-cell therapy is known as a revolutionary treatment option for cancer, owing to its remarkably effective and durable clinical responses. However, market stakeholders need to address major limi...
2022年牵头撰写的《car-t细胞治疗淋巴瘤毒性管理中国专家共识》发表于cancer biol med杂志。2023年本中心牵头制定中国国际科技促进会团团体标准 4项。近5年以第一作者或通讯作者在blood、signal transduction and targeted therapy、journal of hematology & oncology、the lancet haematology、cellular & molecular ...
尽管CAR - T 疗法在肠癌治疗中还面临诸多挑战,但随着研究的不断深入和技术的持续创新,其未来发展前景广阔。相信在不久的将来,CAR - T 疗法有望成为肠癌治疗的重要手段,为肠癌患者带来更多的生存希望。 参考文献: 1. June CH, O'Connor RS, Kawalekar OU, Ghas...
研究成果以“Phase 1 Trial of Prizloncabtagene Autoleucel, a CD19/20 CAR-T for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma”发表在《Blood》(IF:21.0,JCR一区/中科院一区)。同济大学附属同济医院李萍教授、梁爱斌教授分别为该高水平临床研究论文的共同第一作者、最后通讯作者。研究背景近年来,CAR-...
Iyer SP,et al.Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.Lancet Oncol . 2025 Jan;26(1):110-122....
[2]Huang R,et al.Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial[J]. Experimental Hematology & Oncology, 2025, 14(1): 1. https://ehoon...